Advanced Gastric Cancer Clinical Trial
Official title:
A Phase II Open Label Trial of PF-00299804 Monotherapy in Patients With HER-2 Positive Advance Gastric Cancer After Failure of At Least One Prior Chemotherapy Regimen
In case of gastric cancer, the incidence of HER-2 positivity (2+, 3+ on IHC and/or FISH (+))
is reported as similar as that of breast cancer, that is 22% of all cases. A recent ToGA
Trial, phase III trial comparing trastuzumab combined with chemotherapy
(fluoropyrimidine+cisplatin) versus chemotherapy alone in chemotherapy-naïve HER-2 (+)
gastric cancer shows the significant benefit of using trastuzumab in terms of overall
survival and progression-free survival. It provides the clinical evidence of HER-2 as a
reasonable and potential therapeutic target in gastric cancer.
Nowadays, lapatinib, HER-1 and HER-2 dual inhibitor, is also testing under the clinical
trial in gastric cancer.
In preclinical study, PF-00299804 is highly active in HER-2 amplified gastric cancer cell
lines.(SNU preclinical data) So, we plan this phase II trial of PF-00299804 monotherapy in
patients with HER-2 positive advance gastric cancer after failure of at least one
chemotherapy regimen.
The role of HER-2 during carcinogenesis and its prognostic role in breast cancer has been
already well established. Furthermore the value of HER-2 as a reasonable therapeutic target
in breast cancer has translated into the good clinical therapeutic result using HER-2
targeting agent, such as trastuzumab and lapatinib.
In case of gastric cancer, the incidence of HER-2 positivity (2+, 3+ on IHC and/or FISH (+))
is reported as similar as that of breast cancer, that is 22% of all cases. A recent ToGA
Trial, phase III trial comparing trastuzumab combined with chemotherapy
(fluoropyrimidine+cisplatin) versus chemotherapy alone in chemotherapy-naïve HER-2 (+)
gastric cancer shows the significant benefit of using trastuzumab in terms of overall
survival and progression-free survival. It provides the clinical evidence of HER-2 as a
reasonable and potential therapeutic target in gastric cancer.
Nowadays, lapatinib, HER-1 and HER-2 dual inhibitor, is also testing under the clinical
trial in gastric cancer.
PF-00299804 is an orally available, potent, and highly selective irreversible small molecule
inhibitor of the Human Epidermal Growth Factor Receptor (HER) family of tyrosine
kinases:HER-1 (EGFR), HER-2 and HER-4 (HER-3 does not possess kinase activity). PF-00299804
inhibits the tyrosine kinase activity of the HER family through binding at the ATP binding
site, which results in covalent modification of a cystine in the ATP binding pocket. The
unique irreversible and highly selective properties of PF-00299804 for the HER kinase family
results in sustained suppression of receptor tyrosine kinase activity. The long-lasting
inhibition of receptor phosphorylation reduces concern over potentially short plasma
half-lives. Furthermore, the low nanomolar potency and irreversible binding of the intended
targets reduce the need for high peak plasma levels, which in turn could minimize
target-nonspecific toxicities.
In preclinical study, PF-00299804 is highly active in HER-2 amplified gastric cancer cell
lines.(SNU preclinical data)
Overall, the standard of care for advanced gastric cancer has been of modest benefit with
plateau in response rates using various combination chemotherapies. Therefore, development
of treatment options for these advanced gastric cancer patients, especially HER-2 (+)
gastric cancer patients, remains a target of active research.
So, the investigators plan this phase II trial of PF-00299804 monotherapy in patients with
HER-2 positive advance gastric cancer after failure of at least one chemotherapy regimen.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05028933 -
IMC001 for Clinical Research on Advanced Digestive System Malignancies
|
Phase 1 | |
Completed |
NCT00821990 -
Second-line Therapy Versus Supportive Care for Pretreated Advanced Gastric Cancer
|
Phase 3 | |
Recruiting |
NCT04385641 -
Study on the Safety and Effectiveness of UCB-NK Cell Infusion in the Treatment of Advanced Gastric Cancer and Gastroesophageal Cancer
|
N/A | |
Completed |
NCT01248403 -
A Randomized, Double Blind Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma After Prior Chemotherapy
|
Phase 3 | |
Not yet recruiting |
NCT01206218 -
Evaluation of Customized Treatment According to BRCA1 Assessment in Patients With Advanced Gastric Cancer
|
Phase 2/Phase 3 | |
Completed |
NCT01851941 -
A Phase II Trial of Perioperative Chemotherapy With Oxaliplatin, 5-Fluorouracil, Leucovorin(MODIFIED FOLFOX6) in Patients With Locally Advanced Operable Gastric Cancer
|
Phase 2 | |
Completed |
NCT00976768 -
Biweekly FOLFIRI in Advanced Gastric Cancer (AGC) With Failure of Prior Taxane, Fluoropyrimidine, and Cisplatin
|
Phase 2 | |
Active, not recruiting |
NCT03223376 -
A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA)
|
Phase 3 | |
Completed |
NCT03609359 -
Lenvatinib and Pembrolizumab Simultaneous Combination Study
|
Phase 2 | |
Completed |
NCT03350477 -
Bioinformation Therapy for Gastric Cancer
|
Phase 2/Phase 3 | |
Completed |
NCT02935634 -
A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03579784 -
Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer
|
Phase 2 | |
Completed |
NCT02952729 -
Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2
|
Phase 1 | |
Recruiting |
NCT02072317 -
Paclitaxel Plus Raltitrexed Plug Compare With Taxol Second-line Treatment for Advanced Gastric Cancer
|
Phase 2 | |
Completed |
NCT01472250 -
A Prospective and Observational Cohort Study to Evaluate the Treatment Model and Medical Economics of Advanced Gastric Cancer Chemotherapy in Clinical Practice in China
|
N/A | |
Completed |
NCT01503372 -
FLO +/- Pazopanib as First-line Treatment in Advanced Gastric Cancer
|
Phase 2 | |
Terminated |
NCT01402401 -
Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients
|
Phase 2 | |
Recruiting |
NCT01015339 -
Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment in Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction
|
Phase 3 | |
Completed |
NCT02071043 -
Trial of Xeloda and Oxaliplatin (XELOX) as Neo-adjuvant Chemotherapy Followed by Surgery in Advanced Gastric Cancer Patients With Para-aortic Lymph Node Metastasis
|
Phase 2 | |
Completed |
NCT01238055 -
Sunitinib + Docetaxel as Second-line Treatment in Gastric Cancer
|
Phase 2 |